Crizotinib - a multitargeted inhibitor as a molecularly targeted treatment in non small cell lung cancer

Abstract

Author presents an overview of pharmacological and clinical data concerning a new biologicaly targeted drug which is in use in selected non small cell lung cancers (NSCLC). Drug is effective in tumours heaving translocation of EML4-ALK genes, there are some evidence of its efficacy in tumours heaving c-Met amplification or translocation of ROS1 gene.

Keywords

• crizotinib
• EML4-ALK
• translocation
• targeted treatment
• tyrosine kinase inhibitors
• non-small-cell lung cancer
• ROS1 transformation
• c-Met amplification